Download Fast and effective wound healing

Fast and effective wound healing
Negative Pressure Wound Therapy
What are your wound management challenges?
Healthcare professionals and KCI are always looking for ways to heal
wounds faster and more effectively, to improve the quality of life of
patients and to reduce overall therapy costs.
Efficacy?
Healing times?
Patient quality
of life?
Costs?
“
The challenges of effective
wound management are
becoming increasingly complex.
“
C J Moffatt, European Wound Management Association (EWMA). Position Document:
Topical negative pressure in wound management. London: MEP Ltd, 2007.
Is there a better approach
to wound healing?
3
A better approach to wound healing
The scientifically and clinically proven
mechanisms of action behind V.A.C.® Therapy
promote fast and effective wound healing.1–5
Mechanisms
of action
•Moist wound
healing
•Granulation
tissue formation
•Oedema reduction
•Enhanced
perfusion
•Removes wound
exudate containing
molecules that can
inhibit wound
healing
•Stimulates cell
proliferation
Case Report: Trauma wound6
At presentation
Day 0
Day 2
Conclusion
Wound after removal of
hard necrotic tissue.
The undermined area
was filled with V.A.C.®
GranuFoam® Dressing.
After 48 hours the
undermined area had
decreased in size.
After 8 days inpatient and
14 days care in the home
undermining was eliminated
and granulation tissue was
level with wound margin.
A 91-year-old
female with a
haematoma to
the lower leg
secondary to a fall.
The V.A.C.® Therapy advantage
Macrostrain – Tissue level activity
V.A.C.® GranuFoam®
Dressing
Gauze dressing
Microstrain – Cellular level activity
GranuFoam®
Gauze Fibres
Tissue Interaction
Tissue Interaction
Advantages
V.A.C.® GranuFoam® Dressings provide direct,
complete contact with the wound bed. They
contract under negative pressure drawing the
wound edges together and reducing wound
volume. These pulling forces also remove
exudate and infectious materials.
V.A.C.® GranuFoam® Dressings
induce microdeformation of tissue.5
V.A.C.® GranuFoam® Dressings demonstrate
3x more fibroblast migration when compared
with gauze.5
V.A.C.® GranuFoam® Dressings demonstrate
increased proliferation. Cell death is 2.4 x greater
with gauze than with V.A.C.® GranuFoam®
Dressing.5
V.A.C.® Therapy
efficiently
manages large
volumes of
exudate and
accelerates the
healing time of
complex wounds.§
V.A.C.® Therapy: faster 2 and more effective4
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Reduction in ulcer area at Day 28 (cm2)
Faster wound bed preparation
in V.A.C.® Therapy group
V.A.C.® Therapy prepares the wound bed
over twice as fast 2
0
2
Time to wound
bed preparation
was cut from 17
to 7 days with
V.A.C.® Therapy.2
17 days
[10-24]
CONTROL
7 days
[5.7-8.3]
V.A.C® THERAPY
4
6
8
10
p = 0.005
12
14
16
18
20
Duration needed for wound bed preparation (days)
A Randomised Controlled Trial covering 60 chronic leg ulcer patients
compared against advanced moist wound dressings.
Graph adapted from: Vuerstaek et al Journal of Vascular Surgery. 2006.2
Case Report: Chronic wound6
A diabetic
female following
amputation of
the left second
digit and
metatarsal head.
Day minus 30
Day 0
Day 11
Day 54
Amputation of head of
second metatarsal.
Following complications,
and removal of
non-viable tissue.
With no improvement for
1 month, V.A.C.® Therapy
was applied and reduced
slough coverage to 40%
of the wound surface.
At 54 days V.A.C.® Therapy
was discontinued as the
wound bed showed 100%
granulation tissue coverage.
V.A.C.® Therapy is 71% more effective
in reducing wound area4
Wound area
reduced by
4.32 cm2 under
V.A.C.® Therapy
compared to only
2.53 cm2 under
control.4
p < 0.021
CONTROL
4.32 cm2
V.A.C® THERAPY
Diabetic foot ulcers*
2.53 cm2
*Average baseline wound area for
patients treated with V.A.C.® Therapy
is 13.5 cm2 and for patients treated
with AMWT 11.0 cm2.
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Reduction in ulcer area at Day 28 (cm2)
A Randomised Control Trial of 342 patients compared against
predominantly hydrogels and alginates across 37 centres.
Faster wound bed preparation
in V.A.C.® Therapy group
Graph adapted from: Blume et al Diabetes Care. 2008.4
17 days
[10-24]
CONTROL
7 days
[5.7-8.3]
V.A.C® THERAPY
p = 0.005
The healed foot is
functional and can
be accommodated
within semibespoke footwear,
the plantar tissues
show no significant
scarring or areas of
high pressure.§
Impacting positively on healthcare providers and patients
V.A.C.® Therapy cuts treatment
costs by a third7
Average total cost
to achieve 100% healing
Treatment
costs cut by
$12,852 using
V.A.C.® Therapy.7
0
$38.806
CONTROL
$25.954
V.A.C® THERAPY
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
45,000
USD ($)
A Randomised Controlled Trial of 162 patients using V.A.C.® Therapy treating
diabetic foot wounds compared against advanced moist wound care.
Graph adapted from: Apelqvist et al The American Journal of Surgery. 2008.7
Case Report: Acute wound6
A 55-year-old
woman with
necrotising
fasciitis requiring
radical surgical
debridement.
Day 0
Day 0
Day 24
Day 60
Initiation of
V.A.C.® Therapy
after radical surgical
debridement of
abdominal wound.
V.A.C.® Therapy was
applied over exposed
bowel.
The patient was
discharged home on the
V.A.C.® Freedom unit
after a 72% reduction
in wound size.
V.A.C.® Therapy was
discontinued. 98% of
skin graft was taken
successfully.
V.A.C.® Therapy significantly improves
patient quality of life8
Physical
complaints
***
Everyday life
complaints
***
Social life
complaints
***
Psychological
complaints
***
Therapy
burden
***
Complaints with
satisfaction
**p<0.01
Overall quality of life
improved with
V.A.C.® Therapy.8
***p<0.001
**
Overall
complaints
PRIOR TO V.A.C® THERAPY
***
1
1 = no impact
AFTER V.A.C® THERAPY
2
3
4
5
5 = high impact
A questionnaire comparison study in which 98 centres compared data
before and after V.A.C.® Therapy.
Graph adapted from: Augustin et al MMW-Fortschritte der Medizin
Originalien, 2006 8
V.A.C.® Therapy was
used to promote
rapid growth
of granulation
tissue in a patient
with a number
of comorbidities
who was at risk of
delayed healing.§
You care for your patient: we’ll give you the support you need
KCI – your wound care partner
• Introductory training and ongoing education.
• 24-hour customer service to address real-time requirements.
• Continued research and development investment.
• Support from our healthcare economic team with any budget concerns.
• More than 137,000 caregivers trained world wide in 2007 alone.
10
V.A.C.® Therapy is the validated NPWT
• Over 16 Randomised Controlled Trials.
• Over 450 peer-reviewed articles including health economic evidence.
• M
ore than 3 million patients treated to date – with 30,000 patients assisted
world-wide every single day.
• Established mechanisms of action at cellular and tissue levels.
To date over
16
Randomised Control Trials
over
450
peer-reviewed articles
over...
3 million
patients treated with V.A.C.® Therapy
11
V.A.C.® Therapy. Faster, more effective and clinically
proven wound healing.
Prepares the wound
bed over twice as fast.
71% more effective in
reducing wound area.
Cuts treatment
costs by a third.
Significantly improves
quality of life.
Comprehensive customer,
technical training and
support.
Over 16 RCT’s and 450 peerreviewed articles to date.
Can you think of a patient who could benefit from
V.A.C.® Therapy today?
Contact KCI today – 0800 980 8880 – www.kci-medical.com
References
1. Hunter JE, Teot L, Horch R, Banwell PE. Evidence based medicine: vacuum-assisted closure in wound care management. International Wound Journal 2007, 4:256-69.
2. Vuerstaek JD, Jeroen DD, Vainas T, Wuite J, Nelemans P, Neumann MHA, Veraart JCJM. State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuumassisted closure (V.A.C.®) with modern wound dressings. Journal of Vascular Surgery 2006, 44(5):1029-37. 3. Armstrong DG & Lavery LA. Negative Pressure Wound Therapy after partial
Diabetic Foot Amputation: a multicentre, randomised controlled trial. Lancet 2005, 366:1704-10. 4. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of Negative Pressure Wound Therapy
using Vacuum-assisted Closure with Advanced Moist Wound Therapy in the Treatment of Diabetic Foot Ulcers. Diabetes Care 2008, 31:631-36. 5. McNulty AK, Schmidt BS, Feeley T, Kieswetter K. Effects of
negative pressure wound therapy on fibroblast viability, chemotactic signaling, and proliferation in a provisional wound (fibrin) matrix. Wound Repair and Regeneration 2007, 15:838-46. 6. Gray,
D. Russell, F. Timmons, J: Editors. VAC Therapy: An introduction and practical guide. Wounds UK, 2009. 7. Apelqvist J, Armstrong DG, Lavery LA, Boulton AJM. Resource utilization and
economic cost of care based on a randomized trial of Vacuum-assisted Closure therapy in the treatment of diabetic foot wounds. The American Journal of Surgery 2008, 195(6):782-88.
8. Augustin M, Zschocke I. Nutzenbewertung der Ambulanten und Stationaeren V.A.C.® Therapie aus Patientensicht. MMW-Fortschritte der Medizin Originalien 2006, 1(148):S25–32. § Patient
photographs are posed by models.
United Kingdom
KCI Medical Ltd
KCI House
Langford Business Park
Langford Locks
Kidlington OX5 1GF
United Kingdom
24h Customer Support
KCI Advantage Centre
Tel +44 (0) 800 980 8880
Fax +44 (0)1865 840 626
www.kci-medical.com
KCI Product code KCII 1081-01-09-En
kci international
head office
KCI Europe Holding B.V.
Parktoren, 6th Floor
Van Heuven Goedhartlaan 11
PO Box 129
1180 AC Amstelveen
The Netherlands
Tel +31 (0) 20 426 0000
Fax +31 (0) 20 426 0099
www.kci-medical.com
GLOBAL HEAD OFFICE
KCI International
8023 Vantage Drive
San Antonio
TX 78230
U.S.A.
T(free) 1 800 531 5396,
extension 6335
Tel +1 210 255 6335
Fax +1 210 255 6991
www.kci-medical.com
© 2009 KCI Licensing, Inc. All Rights Reserved. All trademarks designated
herein are property of KCI Licensing, Inc, its affiliates and licensors. Those
KCI trademarks designated with the “®” symbol are registered and those
designated with “TM” are considered to be proprietary trademarks or are
pending trademark applications in at least one country where this product/
work is commercialized. Most KCI products referred to herein are subject to
patents or patent applications.